Breast Cancer Research and Treatment

, Volume 122, Issue 3, pp 867–871

IGFBP3 A-202C polymorphism and breast cancer susceptibility: a meta-analysis involving 33,557 cases and 45,254 controls

  • Li-Xin Qiu
  • Lei Yao
  • Hui Yuan
  • Chen Mao
  • Bo Chen
  • Ping Zhan
  • Kai Xue
  • Jian Zhang
  • Xi-Chun Hu


Published data on the association between insulin-like growth factor binding protein 3 (IGFBP3) A-202C polymorphism and breast cancer risk are inconclusive. To derive a more precise estimation of the relationship, a meta-analysis was performed. Crude ORs with 95% CIs were used to assess the strength of association between them. A total of 27 studies including 33,557 cases and 45,254 controls were involved in this meta-analysis. Overall, significantly elevated breast cancer risk was associated with IGFBP3 C allele when all studies were pooled into the meta-analysis (CC vs. AA: OR = 1.06, 95% CI = 1.02–1.11; dominant model: OR = 1.04, 95% CI = 1.00–1.07). In the subgroup analysis by ethnicity, significantly increased risk was found for Caucasians (AC vs. AA: OR = 1.04, 95% CI = 1.00–1.08; CC vs. AA: OR = 1.05, 95% CI = 1.01–1.10; dominant model: OR = 1.04, 95% CI = 1.00–1.08) and Asians (CC vs. AA: OR = 1.35, 95% CI = 1.02–1.78; recessive model: OR = 1.38, 95% CI = 1.05–1.82). When stratified by study design, statistically significantly elevated risk was found among population-based studies (CC vs. AA: OR = 1.06, 95% CI = 1.01–1.11; dominant model: OR = 1.03, 95% CI = 1.00–1.07). In the subgroup analysis by menopausal status, no statistically significantly increased risk was found among premenopausal or postmenopausal women. In conclusion, this meta-analysis suggests that the IGFBP3 C allele is a low-penetrant risk factor for developing breast cancer.


IGFBP3 Polymorphism Breast cancer Susceptibility Meta-analysis 


  1. 1.
    Parkin DM, Bray F, Ferlay J, Pisani P (2005) Global cancer statistics 2002. CA Cancer J Clin 55:74–108CrossRefPubMedGoogle Scholar
  2. 2.
    Lichtenstein P, Holm NV, Verkasalo PK (2000) Environmental and heritable factors in the causation of cancer. N Engl J Med 343:78–85CrossRefPubMedGoogle Scholar
  3. 3.
    Yu H, Rohan T (2000) Role of the insulin-like growth factor family in cancer development and progression. J Natl Cancer Inst 92:1472–1489CrossRefPubMedGoogle Scholar
  4. 4.
    Schedlich LJ, Graham LD (2002) Role of insulin-like growth factor binding protein-3 in breast cancer cell growth. Microsc Res Tech 59:12–22CrossRefPubMedGoogle Scholar
  5. 5.
    Marshman E, Streuli CH (2002) Insulin-like growth factors and insulin-like growth factor binding proteins in mammary gland function. Breast Cancer Res 4:231–239CrossRefPubMedGoogle Scholar
  6. 6.
    Deal C, Ma J, Wilkin F (2001) Novel promoter polymorphism in insulin-like growth factor-binding protein-3: correlation with serum levels and interaction with known regulators. J Clin Endocrinol Metab 86:1274–1280CrossRefPubMedGoogle Scholar
  7. 7.
    Jernstrom H, Deal C, Wilkin F (2001) Genetic and nongenetic factors associated with variation of plasma levels of insulin-like growth factor-I and insulin-like growth factor-binding protein-3 in healthy premenopausal women. Cancer Epidemiol Biomarkers Prev 10:377–384PubMedGoogle Scholar
  8. 8.
    The MARIE-GENICA Consortium on Genetic Susceptibility for Menopausal Hormone Therapy Related Breast Cancer Risk (2009) Polymorphisms in the BRCA1 and ABCB1 genes modulate menopausal hormone therapy associated breast cancer risk in postmenopausal women. Breast Cancer Res Treat. doi:10.1007/s10549-009-0489-8
  9. 9.
    Patel AV, Cheng I, Canzian F, Le Marchand L, Thun MJ, Berg CD (2008) IGF-1, IGFBP-1, and IGFBP-3 polymorphisms predict circulating IGF levels but not breast cancer risk: findings from the Breast and Prostate Cancer Cohort Consortium (BPC3). PLoS One 3:e2578CrossRefPubMedGoogle Scholar
  10. 10.
    Cox A, Dunning AM, Garcia-Closas M et al (2007) A common coding variant in CASP8 is associated with breast cancer risk. Nat Genet 39:352–358CrossRefPubMedGoogle Scholar
  11. 11.
    Slattery ML, Sweeney C, Wolff R et al (2007) Genetic variation in IGF1, IGFBP3, IRS1, IRS2 and risk of breast cancer in women living in Southwestern United States. Breast Cancer Res Treat 104:197–209CrossRefPubMedGoogle Scholar
  12. 12.
    Al-Zahrani A, Sandhu MS, Luben RN et al (2006) IGF1 and IGFBP3 tagging polymorphisms are associated with circulating levels of IGF1, IGFBP3 and risk of breast cancer. Hum Mol Genet 15:1–10CrossRefPubMedGoogle Scholar
  13. 13.
    Canzian F, McKay JD, Cleveland RJ et al (2006) Polymorphisms of genes coding for insulin-like growth factor I and its major binding proteins, circulating levels of IGF-I and IGFBP-3 and breast cancer risk: results from the EPIC study. Br J Cancer 94:299–307CrossRefPubMedGoogle Scholar
  14. 14.
    Cheng I, Penney KL, Stram DO et al (2006) Haplotype-based association studies of IGFBP1 and IGFBP3 with prostate and breast cancer risk: the multiethnic cohort. Cancer Epidemiol Biomarkers Prev 15:1993–1997CrossRefPubMedGoogle Scholar
  15. 15.
    Rohrbacher M, Risch A, Kropp S et al (2005) The A(-336)C insulin-like growth factor binding protein-3 promoter polymorphism is not a modulator of breast cancer risk in Caucasian women. Cancer Epidemiol Biomarkers Prev 14:289–290PubMedGoogle Scholar
  16. 16.
    Wagner K, Hemminki K, Israelsson E et al (2005) Polymorphisms in the IGF-1 and IGFBP3 promoter and the risk of breast cancer. Breast Cancer Res Treat 92:133–140CrossRefPubMedGoogle Scholar
  17. 17.
    Ren ZF, Cai QY, Shu XO et al (2004) Genetic polymorphisms in the IGFBP3 gene: association with breast cancer risk and blood IGFBP-3 protein levels among Chinese women. Cancer Epidemiol Biomarkers Prev 13:1290–1295PubMedGoogle Scholar
  18. 18.
    Cochran WG (1954) The combination of estimates from different experiments. Biometrics 10:101–129CrossRefGoogle Scholar
  19. 19.
    Mantel N, Haenszel W (1959) Statistical aspects of the analysis of data from retrospective studies of disease. J Natl Cancer Inst 22:719–748PubMedGoogle Scholar
  20. 20.
    DerSimonian R, Laird N (1986) Meta-analysis in clinical trials. Control Clin Trials 7:177–188CrossRefPubMedGoogle Scholar
  21. 21.
    Tobias A (1999) Assessing the influence of a single study in the meta-analysis estimate. Stata Tech Bull 8:15–17Google Scholar
  22. 22.
    Egger M, Smith GD, Schneider M, Minder C (1997) Bias in meta-analysis detected by a simple, graphical test. BMJ 315:629–634PubMedGoogle Scholar
  23. 23.
    Giovannucci E (2001) Insulin, insulin-like growth factors and colon cancer: a review of the evidence. J Nutr 131(Suppl 11):S3109–S3120Google Scholar

Copyright information

© Springer Science+Business Media, LLC. 2010

Authors and Affiliations

  • Li-Xin Qiu
    • 1
    • 2
  • Lei Yao
    • 3
  • Hui Yuan
    • 4
  • Chen Mao
    • 5
  • Bo Chen
    • 6
  • Ping Zhan
    • 7
  • Kai Xue
    • 1
    • 2
  • Jian Zhang
    • 1
    • 2
  • Xi-Chun Hu
    • 1
    • 2
  1. 1.Department of Medical Oncology, Cancer HospitalFudan UniversityShanghaiChina
  2. 2.Department of Oncology, Shanghai Medical CollegeFudan UniversityShanghaiChina
  3. 3.State Key Laboratory of Genetic Engineering, Institute of Genetics, School of Life SciencesFudan UniversityShanghaiChina
  4. 4.Department of Epidemiology and Biostatistics, School of Public HealthAnhui Medical UniversityAnhuiChina
  5. 5.Department of Epidemiology, School of Public Health and Tropical MedicineSouthern Medical UniversityGuangzhouChina
  6. 6.Department of Geriatrics, First Affiliated HospitalNanjing Medical UniversityNanjingChina
  7. 7.Department of Respiratory MedicineNanjing Chest HospitalNanjingChina

Personalised recommendations